Agents that target the PI3K/AKT pathway may also prevent the transformation of premalignant gastric lesions into full malignancy, considering the mediator role of the PI3K/AKT/mTOR/HIF-1α axis in tumor-promoting inflammation in H. pylori- and EBV-associated GC [176,180]. This evidence concerns the gene AKT1 and gastric cancer.